Clinical Trial Update: A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC) [Phase 2]

View source ↗

Summary

Phase 2 trial of a PSMA-targeted antibody-drug conjugate in metastatic castration-resistant prostate cancer has completed enrollment and posted results in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• PSMA ADC

Snippet

Sponsor: Progenics Pharmaceuticals, Inc. | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-02-23